Suspension of trading
Intellipharmaceutics International Inc. Stock
Stocks
I4AA
CA4581733090
Pharmaceuticals
OTC Markets Traded|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0445 EUR | -13.59% |
|
-.--% | - |
| Market Cap | 1.28M 1.1M 1.02M 955K 1.79M 121M 1.81M 12.01M 4.68M 59.32M 4.81M 4.71M 206M | P/E Ratio 2021 |
-0.4x | P/E Ratio 2022 | -0.91x |
|---|---|---|---|---|---|
| Enterprise Value | 3.52M 3.04M 2.8M 2.63M 4.93M 333M 4.98M 33.04M 12.87M 163M 13.22M 12.94M 565M | EV / Sales 2021 |
-
| EV / Sales 2022 | 74x |
| Free-Float |
98.24% | Yield 2021 * |
-
| Yield 2022 | - |
| 1 day | -13.59% |
| 3 years | 0.02 | 0.08 | |
| 5 years | 0.01 | 0.18 | |
| 10 years | 0.01 | 35 |
| Manager | Title | Age | Since |
|---|---|---|---|
Amina Odidi
DFI | Director of Finance/CFO | - | - |
| Comptroller/Controller/Auditor | - | 01/04/2007 | |
| Corporate Officer/Principal | - | 01/02/2014 |
| Director | Title | Age | Since |
|---|---|---|---|
Amina Odidi
BRD | Director/Board Member | - | 01/09/2004 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 14/02/24 | Option | Director | 100,000 | 0.3022% | ||
| 13/02/24 | Option | Director | 120,000 | 0.3626% | ||
| 13/02/24 | Option | Chief Executive Officer | 500,000 | 1.5109% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -13.59% | -.--% | -.--% | +2.30% | 1.52M | ||
| -0.70% | -2.09% | +38.78% | +150.32% | 1,007B | ||
| -0.42% | -0.96% | +51.22% | +42.92% | 567B | ||
| +0.39% | -1.56% | +16.27% | +60.06% | 392B | ||
| -0.80% | +1.05% | +20.91% | +18.37% | 328B | ||
| -0.43% | +1.12% | +24.21% | +31.89% | 277B | ||
| +0.64% | -2.55% | +22.80% | +12.69% | 275B | ||
| -1.86% | +4.01% | -43.73% | -49.21% | 196B | ||
| -0.79% | +1.12% | +17.89% | +51.72% | 189B | ||
| +1.80% | +0.91% | +14.27% | +60.59% | 154B | ||
| Average | -1.64% | +0.19% | +16.26% | +38.17% | 338.6B | |
| Weighted average by Cap. | -0.43% | -0.03% | +26.97% | +67.06% |
| 2021 | 2022 | |
|---|---|---|
| Net sales | - | 65.73K 56.64K 52.16K 48.97K 91.95K 6.21M 92.92K 616K 240K 3.04M 247K 241K 10.55M |
| Net income | -5.15M -4.43M -4.08M -3.83M -7.2M -486M -7.27M -48.25M -18.8M -238M -19.31M -18.9M -826M | -2.89M -2.49M -2.3M -2.16M -4.05M -273M -4.09M -27.12M -10.57M -134M -10.85M -10.62M -464M |
| Net Debt | 1.15M 987K 909K 853K 1.6M 108M 1.62M 10.74M 4.18M 53.03M 4.3M 4.21M 184M | 2.24M 1.93M 1.78M 1.67M 3.14M 212M 3.17M 21.03M 8.19M 104M 8.41M 8.24M 360M |
Employees
11
Sector
Pharmaceuticals
- Stock Market
- Stocks
- I4AA Stock
Select your edition
All financial news and data tailored to specific country editions
















